J. Bargonetti, J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives, A proteolytic fragment from the central region of p53 has marked sequencespecific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein, Genes Dev, vol.7, pp.2565-2574, 1993.

J. Bargonetti, I. Reynisdottir, P. N. Friedman, and C. Prives, Sitespecific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53, Genes Dev, vol.6, pp.1886-1898, 1992.

J. H. Bayle, B. Elenbaas, and A. J. Levine, The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity, Proc. Natl. Acad. Sci. USA, vol.92, pp.5729-5733, 1995.

R. Brain and J. R. Jenkins, Human p53 directs DNA strand reassociation and is photolabelled by 8-azido ATP, Oncogene, vol.9, pp.1775-1780, 1994.

L. Buckbinder, R. Talbott, S. Velasco-miguel, I. Takenaka, B. Faha et al., Induction of the growth inhibitor IGF-binding protein 3 by p53, Nature, vol.377, pp.646-649, 1995.

R. Candau, D. M. Scolnick, P. Darpino, C. Y. Ying, T. D. Halazonetis et al., Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity, Oncogene, vol.15, pp.807-816, 1997.

J. Chang, D. Kim, S. W. Lee, K. Y. Choi, and Y. C. Sung, Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein, J. Biol. Chem, vol.270, pp.25014-25019, 1995.

K. Chin, K. Ueda, I. Pastan, and M. M. Gottesman, Modulation of activity of the promoter of the human MDR1 gene by ras and p53, Science, vol.255, pp.459-462, 1992.

Y. Cho, S. Gorina, P. D. Jeffrey, and N. P. Pavletich, Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations, Science, vol.265, pp.346-355, 1994.

G. M. Clore, J. G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto et al., High-resolution structure of the oligomerization domain of p53 by multidimensional NMR, Science, vol.265, pp.386-394, 1994.

S. Deb, C. T. Jackson, M. A. Subler, and D. W. Martin, Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells, J. Virol, vol.66, pp.6164-6170, 1992.

C. J. Di-como and C. Prives, Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay, Oncogene, vol.16, pp.2627-2539, 1998.

G. Farmer, J. Bargonetti, H. Zhu, P. Friedman, R. Prywes et al., Wild-type p53 activates transcription in vitro, Nature, vol.358, pp.83-86, 1992.

G. Farmer, P. Friedlander, J. Colgan, J. L. Manley, and C. Prives, Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein, Nucleic Acids Res, vol.24, pp.4281-4288, 1996.

S. Fields and S. K. Jang, Presence of a potent transcription activating sequence in the p53 protein, Science, vol.249, pp.1046-1049, 1990.

J. Flaman, T. Frebourg, V. Moreau, F. Charbonnier, C. Martin et al., A simple p53 functional assay for screening cell lines, blood, and tumors, Proc. Natl. Acad. Sci. USA, vol.92, pp.3963-3967, 1995.

K. Forrester, S. E. Lupold, V. L. Ott, C. H. Chay, V. Band et al., Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent, Oncogene, vol.10, pp.2103-2111, 1995.

M. W. Frazier, X. He, J. Wang, Z. Gu, J. L. Cleveland et al., Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain, Mol. Cell. Biol, vol.18, pp.3735-3743, 1998.

P. Friedlander, Y. Haupt, C. Prives, and M. Oren, A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis, Mol. Cell. Biol, vol.16, pp.4961-4971, 1996.

P. N. Friedman, X. Chen, J. Bargonetti, and C. Prives, The p53 protein is an unusually shaped tetramer that binds directly to DNA, Proc. Natl. Acad. Sci. USA, vol.90, pp.3319-3323, 1993.

C. B. Gaiddon, A. Monnier, L. Mercken, and J. Loeffler, Genomic effects of the putative oncogene G alpha s. Chronic transcriptional activation of the c-fos proto-oncogene in endocrine cells, J. Biol. Chem, vol.269, pp.22663-22671, 1994.

T. Gottlieb and M. Oren, Biochim. Biophys. Acta, vol.1287, pp.77-102, 1996.

A. Gualberto, K. Aldape, K. Kozakiewicz, and T. Tlsty, An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control, Proc. Natl. Acad. Sci. USA, vol.95, pp.5166-5171, 1998.

J. A. Guthrie and G. R. Fink, Methods in enzymology, vol.194, 1991.

M. Hachiya, A. Chumakov, C. W. Miller, M. Akashi, J. Said et al., Mutant p53 proteins behave in a dominant, negative fashion in vivo, Anticancer Res, vol.14, pp.1853-1860, 1994.

T. D. Halazonetis, L. J. Davis, and A. N. Kandil, Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA, EMBO J, vol.12, pp.1021-1028, 1993.

T. D. Halazonetis and A. N. Kandil, Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants, EMBO J, vol.12, pp.5057-5064, 1993.

A. J. Hale, C. A. Smith, L. C. Sutherland, V. E. Stoneman, V. L. Longthorne et al., Apoptosis: molecular regulation of cell death, Eur. J. Biochem, vol.236, pp.1-26, 1996.

C. Ishioka, T. Frebourg, Y. Yan, M. Vidal, S. H. Friend et al., Screening patients for heterozygous p53 mutations using a functional assay in yeast, Nat. Genet, vol.5, pp.124-129, 1993.

L. Jayaraman, K. G. Murthy, C. Zhu, T. Curran, S. Xanthoudakis et al., Identification of redox/repair protein Ref-1 as a potent activator of p53, Genes Dev, vol.11, pp.558-570, 1997.

P. D. Jeffrey, S. Gorina, and N. P. Pavletich, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, vol.267, pp.1498-1502, 1995.

C. A. Jost, M. C. Marin, and W. G. Kaelin, p73 is a human p53-related protein that can induce apoptosis, Nature, vol.389, pp.191-194, 1997.

M. Kaghad, H. Bonnet, A. Yang, L. Creancier, J. Biscan et al.,

. Caput, Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers, Cell, vol.90, pp.809-819, 1997.

S. E. Kern, K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman et al., Identification of p53 as a sequence-specific DNAbinding protein, Science, vol.252, pp.1708-1711, 1991.

S. E. Kern, J. A. Pientenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler et al., Oncogenic forms of p53 inhibit p53-regulated gene expression, Science, vol.256, pp.827-830, 1992.

A. Kieser, H. A. Weich, G. Brandner, D. Marme, and W. Kolch, Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression, Oncogene, vol.9, pp.963-969, 1994.

L. J. Ko and C. Prives, p53: puzzle and paradigm, Genes Dev, vol.10, pp.1054-1072, 1996.

G. M. Lamm, P. Steinlein, M. Cotten, and G. Christofori, A rapid, quantitative and inexpensive method for detecting apoptosis by flow cytometry in transiently transfected cells, Nucleic Acids Res, vol.25, pp.4855-4857, 1997.

W. Lee, T. S. Harvey, Y. Yin, P. Yau, D. Litchfield et al., Solution structure of the tetrameric minimum transforming domain of p53, Nat. Struct. Biol, vol.1, pp.877-890, 1994.

Y. Lee, Y. Chen, L. S. Chang, and L. F. Johnson, Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein, Exp. Cell Res, vol.234, pp.270-276, 1997.

A. J. Levine, p53, the cellular gatekeeper for growth and division, Cell, vol.88, pp.323-331, 1997.

J. H. Ludes-meyers, M. A. Subler, C. V. Shivakumar, R. M. Munoz, P. Jiang et al., Transcriptional activation of the human epidermal growth factor receptor promoter by human p53, Mol. Cell. Biol, vol.16, pp.6009-6019, 1996.

R. L. Ludwig, S. Bates, and K. H. Vousden, Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function, Mol. Cell. Biol, vol.16, pp.4952-4960, 1996.

L. Margulies and P. B. Sehgal, Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species, J. Biol. Chem, vol.268, pp.15096-15100, 1993.

D. Michalovitz, O. Halevy, and M. Oren, Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53, Cell, vol.62, pp.671-680, 1990.

C. W. Miller, A. Chumakov, J. Said, D. L. Chen, A. Aslo et al., Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription, Oncogene, vol.8, pp.1815-1824, 1993.

J. Milner and E. A. Medcalf, Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation, Cell, vol.65, pp.765-774, 1991.

J. Milner, E. A. Medcalf, and A. C. Cook, Tumor suppressor p53: analysis of wild-type and mutant p53 complexes, Mol. Cell. Biol, vol.11, pp.12-19, 1991.

T. Miyashita and J. C. Reed, Tumor suppressor p53 is a direct transcriptional activator of the human bax gene, Cell, vol.80, pp.293-299, 1995.

M. Osada, M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru et al., Cloning and functional analysis of human p51, which structurally and functionally resembles p53, Nat. Med, vol.4, pp.839-843, 1998.

N. P. Pavletich, K. A. Chambers, and C. O. Pabo, The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots, Genes Dev, vol.7, pp.2556-2564, 1993.

N. S. Prabhu, K. Somasundaram, K. Satyamoorthy, M. Herlyn, and W. El-deiry, P73?, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells, Int. J. Oncol, vol.13, pp.5-9, 1998.

M. Ptashne and A. A. Gann, Activators and targets, Nature, vol.346, pp.329-331, 1990.

R. Rainwater, D. Parks, M. E. Anderson, P. Tegtmeyer, and K. Mann, Role of cysteine residues in regulation of p53 function, Mol. Cell. Biol, vol.15, pp.3892-3903, 1995.

L. Raycroft, H. Wu, and G. Lozano, Transcriptional activation by wild-type p53 but not transforming mutants of the p53 anti-oncogene, Science, vol.249, pp.1049-1051, 1990.

L. Raycroft, J. R. Schmidt, K. Yoas, M. Hao, and G. Lozano, Analysis of p53 mutants for transcriptional activity, Mol. Cell. Biol, vol.11, pp.6067-6074, 1991.

M. Reed, B. Woelker, P. Wang, Y. Wang, M. E. Anderson et al., The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation, Proc. Natl. Acad. Sci. USA, vol.92, pp.9455-9459, 1995.

M. D. Rose, F. Winston, and P. Heiter, Laboratory course manual for methods in yeast genetics, 1990.

H. Schmale and C. Bamberger, A novel protein with strong homology to the tumor suppressor p53, Oncogene, vol.15, pp.1363-1367, 1997.

M. Senoo, N. Seki, M. Ohira, S. Sugano, M. Watanabe et al., A second p53-related protein, p73L, with high homology to p73, Biochem. Biophys. Res. Commun, vol.248, pp.603-607, 1998.

E. Shaulian, A. Zauberman, D. Ginsberg, and M. Oren, Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding, Mol. Cell. Biol, vol.12, pp.5581-5592, 1992.

T. J. Silhavy, M. L. Berman, and L. W. Enquist, Experiments with gene fusions, 1984.

S. Srivastava, S. Wang, Y. A. Tong, K. Pirollo, and E. H. Chang, Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53, Oncogene, vol.8, pp.2449-2456, 1993.

M. Tada, S. Sakuma, R. D. Iggo, H. Saya, Y. Sawamura et al., Monitoring adenoviral p53 transduction efficiency by yeast functional assay, Gene Ther, vol.5, pp.339-344, 1998.

Y. Tsutsumi-ishi, A. Tadokoro, F. Hanaoka, and N. Tsuchida, Response of heat shock element within the human HSP70 promoter to mutated p53 genes, Cell Growth Differ, vol.6, pp.1-8, 1995.

T. Ueba, T. Nosaka, J. A. Takahashi, F. Shibata, R. Z. Florkiewicz et al., Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells, Proc. Natl. Acad. Sci. USA, vol.91, pp.9009-9013, 1994.

T. Unger, J. A. Mietz, M. Scheffner, C. L. Yee, and P. M. Howley, Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression, Mol. Cell. Biol, vol.13, pp.5186-5194, 1993.

T. Unger, M. M. Nau, S. Segal, and J. D. Minna, p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer, EMBO J, vol.11, pp.1383-1390, 1992.

B. Vogelstein and K. W. Kinzler, function and dysfunction, Cell, vol.70, pp.523-526, 1992.

K. K. Walker and A. J. Levine, Identification of a novel p53 functional domain that is necessary for efficient growth suppression, Proc. Natl. Acad. Sci. USA, vol.93, pp.15335-15340, 1996.

Y. Wang, M. Reed, P. Wang, J. E. Stenger, G. Mayr et al., p53 domains: identification and characterization of two autonomous DNA-binding regions, Genes Dev, vol.7, pp.2575-2586, 1993.

A. Yang, M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming et al., p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities, Mol. Cell, vol.2, pp.305-316, 1998.